Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows

Sedana Medical AB (publ)

17/07/2026 06:10

Overview
Sweden medtech firm's Q2 sales were flat at constant FX, down 1% in SEK
Company improved Q2 EBITDA and gross margin despite weak German market
Sedana Medical submitted FDA New Drug Application for US market entry

Outlook
Sedana Medical reiterates full-year guidance of approaching EBITDA break-even at Group level
Company expects mid- to high-single-digit EBITDA margin in ex-US business for full year
Sedana Medical says FDA review of US NDA submission is underway; launch preparations ongoing

Result Drivers
WEAK GERMAN MARKET - Co said sales in Germany declined due to fewer ICU patients, offsetting growth elsewhere
SALES ACCELERATION OUTSIDE GERMANY - Co reported broad-based sales growth in other direct and distributor markets
IMPROVED GROSS MARGIN - Higher gross margin driven by lower device costs after supplier acquisition and favorable sales mix

Company press release: ID:nMFN1Cwp81

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
 
SEK 49.10 mln
 
Q2 Adjusted EPS
 
-SEK 0.10
 
Q2 Net Income
 
-SEK 9.60 mln
 
Q2 Cash Flow From Operating Activities
 
-SEK 7.70 mln
 
Q2 EBITDA
 
-SEK 1.90 mln
 
Q2 EBIT Margin
 
-19.00%
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)